Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Korean Patients With Rheumatoid Arthritis
NCT06625242Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of filgotinib in rheumatoid arthritis (RA), sponsored by Eisai Co., Ltd. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06625242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625242.